Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae rolled up several ...

A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. San Francisco genetic testing firm Invitae succeeded this ...

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical ...

(Reuters) - Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after ...

Invitae, a genetic-testing business backed by investors including SoftBank Group and Cathie Wood’s ARK Investment Management, has filed for bankruptcy, blaming poorly-timed acquisitions, macroeconomic ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo for Labcorp is displayed on a screen on the floor of the NYSE in New York (Reuters) - Laboratory service provider Labcorp ...